Adult Neurogenesis Therapeutics: Investment Landscape

[Adult neurogenesis](/mechanisms/adult-neurogenesis-neurodegeneration) refers to the process of generating new [neurons](/entities/neurons) in the adult brain, primarily occurring in the [hippocampus](/brain-regions/hippocampus) (subgranular zone of dentate gyrus) and [olfactory bulb](/brain-regions/olfactory-bulb). This investment landscape analysis examines therapeutic approaches aimed at enhancing adult neurogenesis as a treatment strategy for neurodegenerative diseases, particularly [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease).

Executive Summary

[Adult neurogenesis](/mechanisms/adult-neurogenesis-neurodegeneration) refers to the process of generating new [neurons](/entities/neurons) in the adult brain, primarily occurring in the [hippocampus](/brain-regions/hippocampus) (subgranular zone of dentate gyrus) and [olfactory bulb](/brain-regions/olfactory-bulb). This investment landscape analysis examines therapeutic approaches aimed at enhancing adult neurogenesis as a treatment strategy for neurodegenerative diseases, particularly [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease).

Executive Summary

The adult neurogenesis therapeutics field represents an emerging area of regenerative medicine for neurodegenerative diseases. While the field is still early-stage compared to traditional neurotransmitter-based approaches, significant investment has flowed into companies developing stem cell therapies, small molecules, and biologics aimed at stimulating neural stem cell proliferation, differentiation, and functional integration.[@neurogenesis2024] The global market for neurogenesis-based therapeutics is projected to grow from approximately $2.8 billion in 2025 to $8.5 billion by 2035, representing a compound annual growth rate (CAGR) of ~12%.[@neurogenesisbased2025]

Key challenges include [blood-brain barrier](/entities/blood-brain-barrier) penetration, ensuring proper neuronal differentiation and connectivity, and immune rejection for cell-based therapies. Recent advances in [iPSC](/technologies/induced-pluripotent-stem-cells) technology and gene editing have accelerated progress, with several candidates now entering clinical trials.[@ipsc2024]

Pipeline Overview

As of early 2026, the adult neurogenesis therapeutic pipeline includes:[@clinicaltrialsgov]

| Phase | Number of Trials/Programs | Percentage |
|-------|-------------------------|------------|
| Pre-clinical | ~80+ | - |
| Phase 1 | 8 | 24% |
| Phase 2 | 12 | 36% |
| Phase 3 | 3 | 9% |
| Approved | 0 | 0% |

Note: No therapies targeting adult neurogenesis have yet received regulatory approval. The field remains predominantly in research and development phases.

Mechanism Breakdown

1. Neural Stem Cell Transplantation (~35% of pipeline)

Cell replacement therapy using various stem cell sources:

| Approach | Cell Type | Company | Stage | Indication |
|----------|-----------|---------|-------|------------|
| STEM-PD | ESC-derived dopaminergic neurons | Lundbeck/Oxford | Phase 1/2 | PD |
| NSI-566 | Neural stem cells | Neuralstem | Phase 2 | ALS |
| HPC | Autologous CD34+ cells | Stemedica | Phase 1/2 | PD |
| INNO-401 | iPSC-derived dopaminergic neurons | INNO Biotechnology | Pre-clinical | PD |
| BRG | iPSC-derived | BlueRock Therapeutics (Bayer) | Phase 1 | PD |

Advantage: Direct cell replacement providing potential functional recovery[@stem2024]

Challenge: Immune rejection, tumor risk, ethical considerations, proper circuit integration

2. Endogenous Neurogenesis Stimulation (~30% of pipeline)

Small molecules and biologics promoting resident neural stem cell activation:

| Candidate | Target | Company | Phase | Indication |
|-----------|--------|---------|-------|------------|
| NSI-189 | Phosphodiesterase | Neuralstem | Phase 2 | MDD/AD |
| LM22A-4 | TrkB agonist | Lundbeck | Pre-clinical | PD |
| SC1 | [GSK-3β](/entities/gsk3-beta) inhibitor | Stemgent | Pre-clinical | AD |
| Bromodeoxyuridine | DNA synthesis | Various | Research | - |
| Epo | Erythropoietin receptor | Various | Pre-clinical | Stroke |

Advantage: Avoids surgical implantation, lower immunogenic risk[@neural2023]

Challenge: Limited BBB penetration, variable efficacy

3. Exercise and Environmental Enrichment (~10% of pipeline)

Non-pharmacological approaches:

| Intervention | Mechanism | Evidence Level | Status |
|-------------|-----------|----------------|--------|
| Aerobic exercise | BDNF, IGF-1 | Strong | Clinical |
| Cognitive training | Neuroplasticity | Moderate | Clinical |
| Dietary restriction | [Autophagy](/entities/autophagy), metabolism | Pre-clinical | Research |
| Enriched environment | Multiple pathways | Pre-clinical | Research |

Advantage: Safe, accessible, multiple benefits beyond neurogenesis[@bloodbrain2024]

Challenge: Adherence, difficulty standardizing, variable individual response

4. Gene Therapy for Neurotrophic Factors (~15% of pipeline)

Viral vector delivery of growth factors:

| Approach | Factor | Company | Phase | Indication |
|----------|--------|---------|-------|------------|
| AAV2-NTN | Neurturin | Ceregene | Phase 2 | PD |
| AAV2-GDNF | GDNF | Ceregene | Phase 1/2 | PD |
| AAV2-ARTN | Artemin | Asklepios | Pre-clinical | PD |
| CERE-110 | NGF | Ceregene | Phase 2 | AD |

Advantage: Sustained protein expression, targeted delivery[@ceregenes2023]

Challenge: Surgical delivery, potential off-target effects, immunogenicity

5. Small Molecule Neurogenesis Enhancers (~10% of pipeline)

| Drug | Target | Company | Phase | Indication |
|------|--------|---------|-------|------------|
| [Donepezil](/entities/donepezil) | AChE inhibitor | Eisai | Approved | AD |
| Memantine | NMDA antagonist | Allergan | Approved | AD |
| Tideglusib | GSK-3β inhibitor | Everest Therapeutics | Phase 2 | AD |
| AGBL2 inhibitors | CCKBR modulation | Various | Pre-clinical | - |

Note: Some approved AD drugs may have neurogenesis effects but are not specifically approved for this indication.

Clinical Trial Design Trends

Patient Selection Criteria

Modern neurogenesis trials increasingly focus on:

• Confirmed neurodegeneration: Biomarker-positive patients with clear diagnosis
• Early-stage disease: Mild cognitive impairment or early dementia
• Baseline neurogenesis assessment: MRI volumetry, FDG-PET metabolic markers
• Genetic stratification: APOE4 status, BDNF Val66Met polymorphism

Endpoints

| Endpoint Type | Common Measures | Challenges |
|---------------|-----------------|------------|
| Cognitive | ADAS-Cog, MoCA, MMSE | Variable baseline, practice effects |
| Functional | ADCS-ADL, iADL | Floor/ceiling effects |
| Biomarker | MRI volume, CSF BDNF, neurofilament | Validation ongoing |
| Survival | Time to progression | Requires long follow-up |

Sponsor Landscape

By Type

| Sponsor Type | Percentage | Examples |
|--------------|------------|----------|
| Pharmaceutical | 45% | Lundbeck, Bayer/BlueRock, Biogen |
| Biotechnology | 35% | Neuralstem, Stemedica, INNO Biotechnology |
| Academic/Research | 15% | Universities, NIH |
| Device/Tech | 5% | NeuroPace |

Key Players

| Company | Focus Area | Stage | Investment |
|---------|------------|-------|------------|
| BlueRock Therapeutics (Bayer) | iPSC dopaminergic neurons | Phase 1 | ~$1B acquisition |
| Lundbeck | Cell therapy, small molecules | Phase 1/2 | ~$500M R&D |
| Neuralstem | Neural stem cells | Phase 2 | ~$100M |
| Stemedica | Autologous stem cells | Phase 1/2 | ~$50M |
| Biogen | Neurotrophic factors | Phase 1 | ~$200M |

Funding Trends

Recent Investment Activity (2024-2026)

| Year | Total Funding (Est.) | Key Deals |
|------|---------------------|-----------|
| 2024 | $850M | BlueRock acquisition ($1B), Lundbeck partnerships |
| 2025 | $1.2B | Phase 2 readouts, new biotech entrants |
| 2026 YTD | $400M+ | Continued Series funding, pharma partnerships |

Funding estimates based on public disclosures and industry reports.

Gap Analysis

Unmet Needs

Underrepresented Areas

| Area | Current Activity | Opportunity |
|------|------------------|-------------|
| ALS | Low | High - motor neuron replacement |
| Huntington's | Moderate | High - striatal neuron replacement |
| Multiple System Atrophy | Low | Moderate - oligodendrocyte + neuron |
| Vascular Dementia | Low | Moderate - vascular + neural repair |
| Pediatric neurodevelopmental | Low | High - early intervention |

Cross-Links to NeuroWiki

• [Adult Neurogenesis Mechanism Page](/mechanisms/adult-neurogenesis-neurodegeneration)
• [Neural Stem Cells](/cell-types/neural-stem-cells)
• [Hippocampus](/brain-regions/hippocampus)
• [iPSC Technology](/technologies/induced-pluripotent-stem-cells)
• [GDNF Pathway](/mechanisms/gdnf-signaling-neurodegeneration)
• [BDNF Signaling](/mechanisms/bdnf-signaling-neurodegeneration)
• [Alzheimer's Treatment](/therapeutics/alzheimers-disease-treatment)
• [Parkinson's Treatment](/therapeutics/parkinson-disease-treatment)

See Also

• [Adult neurogenesis](/content/genes)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's disease](/diseases/parkinsons-disease)
• [Blood-Brain Barrier](/entities/blood-brain-barrier)
• [iPSC](/technologies/ipsc-disease-models)
• [Adult Neurogenesis Mechanism Page](/content/genes)
• [Neural Stem Cells](/cell-types/subventricular-zone-neural-stem-cells)
• iPSC Technology

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [ClinicalTrials.gov](https://clinicaltrials.gov/)

References